熱門資訊> 正文
细胞疗法开发商Artiva再次申请1亿美元IPO
2024-06-29 22:07
- Cell therapy developer Artiva Biotherapeutics (ARTV), whose collaborators include German biotech Affimed (AFMD), has filed with the SEC to raise up to $100M in an initial public offering under the ticker symbol "ARTV."
- The San Diego, California-based biotech previously filed for a $100M IPO in 2021 to list under the ticker symbol "RTVA" and withdrew its plans in late 2022.
- Artiva (RTVA) instead signed an agreement with Affimed (AFMD) to collaborate on a drug combo involving its lead asset, AlloNK, an NK cell therapy previously known as AB-101.
- Artiva (ARTV), a cancer drug developer focused on developing "off-the-shelf" product candidates derived from donor cells (allogeneic), is currently testing AlloNK in a Phase 1/1b trial for lupus nephritis, which is set to generate data in H1 2025.
More on Artiva Biotherapeutics, Inc.
- Financial information for Artiva Biotherapeutics, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
